Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645136 | 1.00 | FFAR4 (0.54) | FFAR4KDM4EMEN1KMT2AFFAR1 | |
| SCHEMBL12993003 | 0.86 | SIRT2 (0.49) | FFAR4KDM4EMEN1KMT2AHDAC8 | |
| SCHEMBL11244569 | 0.86 | FFAR1 (0.76) | FFAR4KDM4EMEN1KMT2AFFAR1 | |
| SCHEMBL28191746 | 0.85 | FFAR4 (0.52) | FFAR4KDM4EMEN1KMT2AFFAR1 | |
| SCHEMBL6173881 | 0.85 | FFAR4 (0.52) | FFAR4KDM4EMEN1KMT2AFFAR1 | |
| SCHEMBL901880 | 0.85 | FFAR4 (0.55) | FFAR4KDM4EKMT2AFFAR1TAAR1 | |
| SCHEMBL14026853 | 0.85 | MAOB (0.47) | FFAR4KDM4EMEN1KMT2AFFAR1 | |
| SCHEMBL10868609 | 0.85 | FFAR4 (0.45) | FFAR4KDM4EMEN1KMT2AFFAR1 | |
| SCHEMBL10868603 | 0.85 | FFAR4 (0.45) | FFAR4KDM4EMEN1KMT2AFFAR1 | |
| SCHEMBL12646504 | 0.85 | MAOB (0.57) | FFAR4FFAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921606-B2 | Process for cinacalcet hydrochloride | HETERO RESEARCH FOUNDATION (IN) | 2014-12-30 | — | — | US | claimed |
| US-20130178654-A1 | PROCESS FOR CINACALCET HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2013-07-11 | — | — | US | claimed |
| EP-2593422-A1 | PROCESS FOR CINACALCET HYDROCHLORIDE | Hetero Research Foundation (IN) | 2013-05-22 | — | — | EP | claimed |
| WO-2012007954-A1 | PROCESS FOR CINACALCET HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2012-01-19 | — | — | WO | claimed |
| CN-111196759-B | Preparation method of cinacalcet hydrochloride and intermediate thereof | 上海博志研新药物技术有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-111196759-A | Preparation method of cinacalcet hydrochloride and intermediate thereof | 上海博志研新药物技术有限公司 | 2020-05-26 | — | — | CN | disclosed |
| US-8921606-B2 | Process for cinacalcet hydrochloride | HETERO RESEARCH FOUNDATION (IN) | 2014-12-30 | — | — | US | disclosed |
| US-20130178654-A1 | PROCESS FOR CINACALCET HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2013-07-11 | — | — | US | disclosed |
| US-8454978-B2 | Immunostimulating agent | AJINOMOTO CO., INC. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455700-B2 | Method for producing phenylalkane-1-ols | BASF SE (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2593422-A1 | PROCESS FOR CINACALCET HYDROCHLORIDE | Hetero Research Foundation (IN) | 2013-05-22 | — | — | EP | disclosed |
| EP-2321241-B1 | METHOD FOR PRODUCING PHENYLALKANE-1-OLS | BASF SE (DE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2010012675-A1 | METHOD FOR PRODUCING PHENYLALKANE-1-OLS | BASF SE (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009014268-A1 | FLUORINE-CONTAINING ORGANOSULFUR COMPOUND AND PESTICIDAL COMPOSITION COMPRISING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-29 | — | — | WO | disclosed |
| US-20080261926-A1 | Pharmaceutical Calcimimetics | CONCERT PHARMACEUTICALS INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261926-A1 | Pharmaceutical Calcimimetics | CONCERT PHARMACEUTICALS INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008122010-A1 | PHARMACEUTICAL CALCIMIMETICS | CONCERT PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008035381-A2 | PROCESS FOR THE PREPARATION OF AMINE DERIVATIVES AS CALCIMIMETICS | IND-SWIFT LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261926-A1 | Pharmaceutical Calcimimetics | CASR, CALCR, PTH1R | FFAR4 482/4885KDM4E 4385/4885MEN1 624/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | FFAR4 132/4885KDM4E 3958/4885MEN1 4682/4885 |
| US-20130178654-A1 | PROCESS FOR CINACALCET HYDROCHLORIDE | CA4, CA9, CA14 | FFAR4 2013/4885KDM4E 831/4885MEN1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.